Clinical Trial

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

Study acronym: OLYMPUS
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).
Protocol Amendment History 8 changes
notable Trial sites expanded: 108 -> 111 locations 2026-08-04
notable Trial sites expanded: 102 -> 108 locations 2026-07-21
notable Trial sites expanded: 98 -> 102 locations 2026-06-30
notable Trial sites expanded: 93 -> 98 locations 2026-06-06
notable Trial sites expanded: 86 -> 93 locations 2026-05-12
notable Trial sites expanded: 79 -> 86 locations 2026-04-25
notable Trial sites expanded: 73 -> 79 locations 2026-04-22
notable Trial sites expanded: 69 -> 73 locations 2026-03-31
Trial Details
NCT Number NCT07204275
Lead Sponsor Vertex Pharmaceuticals Incorporated
Collaborators: Zai Lab (Shanghai) Co., Ltd. (for China only)
Conditions Primary Membranous Nephropathy
Enrollment 176 participants
Start Date 2025-09-30
Primary Completion 2028-12-29 (estimated)
Study Completion 2028-12-29 (estimated)
Updated on ClinicalTrials.gov 2026-08-03